[go: up one dir, main page]

CA3173268A1 - Materiels et methodes de modulation d'une reponse immunitaire - Google Patents

Materiels et methodes de modulation d'une reponse immunitaire

Info

Publication number
CA3173268A1
CA3173268A1 CA3173268A CA3173268A CA3173268A1 CA 3173268 A1 CA3173268 A1 CA 3173268A1 CA 3173268 A CA3173268 A CA 3173268A CA 3173268 A CA3173268 A CA 3173268A CA 3173268 A1 CA3173268 A1 CA 3173268A1
Authority
CA
Canada
Prior art keywords
amino acid
acid sequence
antibody
seq
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3173268A
Other languages
English (en)
Inventor
Rajkumar Ganesan
Iqbal S. Grewal
Sanjaya Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/031749 external-priority patent/WO2020227457A1/fr
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CA3173268A1 publication Critical patent/CA3173268A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des molécules anti-TRGV9 telles que des anticorps anti-TRGV9 ou des fragments de liaison à l'antigène de celles-ci. L'invention concerne également des acides nucléiques codant pour les anticorps, des compositions comprenant les anticorps, des procédés de production des anticorps, et des procédés d'utilisation des anticorps pour le traitement ou la prévention de maladies.
CA3173268A 2020-02-27 2021-02-26 Materiels et methodes de modulation d'une reponse immunitaire Pending CA3173268A1 (fr)

Applications Claiming Priority (91)

Application Number Priority Date Filing Date Title
US202062982505P 2020-02-27 2020-02-27
US202062982602P 2020-02-27 2020-02-27
US202062982492P 2020-02-27 2020-02-27
US202062982525P 2020-02-27 2020-02-27
US202062982591P 2020-02-27 2020-02-27
US202062982374P 2020-02-27 2020-02-27
US202062982535P 2020-02-27 2020-02-27
US202062982664P 2020-02-27 2020-02-27
US202062982469P 2020-02-27 2020-02-27
US202062982669P 2020-02-27 2020-02-27
US202062982574P 2020-02-27 2020-02-27
US202062982478P 2020-02-27 2020-02-27
US202062982462P 2020-02-27 2020-02-27
US202062982548P 2020-02-27 2020-02-27
US62/982,669 2020-02-27
US62/982,492 2020-02-27
US62/982,535 2020-02-27
US62/982,591 2020-02-27
US62/982,505 2020-02-27
US62/982,602 2020-02-27
US62/982,664 2020-02-27
US62/982,574 2020-02-27
US62/982,525 2020-02-27
US62/982,478 2020-02-27
US60/982,469 2020-02-27
US62/982,374 2020-02-27
US62/982,548 2020-02-27
US62/982,462 2020-02-27
US202062989018P 2020-03-13 2020-03-13
US202062989075P 2020-03-13 2020-03-13
US202062989042P 2020-03-13 2020-03-13
US202062989036P 2020-03-13 2020-03-13
US202062989027P 2020-03-13 2020-03-13
US202062989068P 2020-03-13 2020-03-13
US202062989045P 2020-03-13 2020-03-13
US202062989002P 2020-03-13 2020-03-13
US202062989024P 2020-03-13 2020-03-13
US202062989010P 2020-03-13 2020-03-13
US202062988996P 2020-03-13 2020-03-13
US202062989006P 2020-03-13 2020-03-13
US202062989052P 2020-03-13 2020-03-13
US202062989057P 2020-03-13 2020-03-13
US62/989,002 2020-03-13
US62/989,024 2020-03-13
US62/989,027 2020-03-13
US62/989,068 2020-03-13
US62/989,010 2020-03-13
US62/989,045 2020-03-13
US62/989,075 2020-03-13
US62/989,018 2020-03-13
US62/989,042 2020-03-13
US62/989,006 2020-03-13
US62/989,036 2020-03-13
US62/989,057 2020-03-13
US62/988,996 2020-03-13
US62/989,052 2020-03-13
PCT/US2020/031749 WO2020227457A1 (fr) 2019-05-08 2020-05-07 Matières et méthodes pour moduler l'immunité médiée par les lymphocytes t
USPCT/US2020/031749 2020-05-07
US202063074759P 2020-09-04 2020-09-04
US202063074735P 2020-09-04 2020-09-04
US202063074962P 2020-09-04 2020-09-04
US202063074839P 2020-09-04 2020-09-04
US202063074925P 2020-09-04 2020-09-04
US202063074893P 2020-09-04 2020-09-04
US202063074854P 2020-09-04 2020-09-04
US202063074937P 2020-09-04 2020-09-04
US202063074749P 2020-09-04 2020-09-04
US202063074946P 2020-09-04 2020-09-04
US202063074676P 2020-09-04 2020-09-04
US202063074655P 2020-09-04 2020-09-04
US202063074700P 2020-09-04 2020-09-04
US202063074903P 2020-09-04 2020-09-04
US63/074,854 2020-09-04
US63/074,962 2020-09-04
US63/074,903 2020-09-04
US63/074,759 2020-09-04
US63/074,937 2020-09-04
US63/074,925 2020-09-04
US63/074,676 2020-09-04
US63/074,749 2020-09-04
US63/074,735 2020-09-04
US63/074,839 2020-09-04
US63/074,700 2020-09-04
US63/074,893 2020-09-04
US63/074,655 2020-09-04
US63/074,946 2020-09-04
US202063112475P 2020-11-11 2020-11-11
US202063112462P 2020-11-11 2020-11-11
US63/112,475 2020-11-11
US63/112,462 2020-11-11
PCT/US2021/019766 WO2021173896A1 (fr) 2020-02-27 2021-02-26 Matériels et méthodes de modulation d'une réponse immunitaire

Publications (1)

Publication Number Publication Date
CA3173268A1 true CA3173268A1 (fr) 2021-09-02

Family

ID=77492135

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3173268A Pending CA3173268A1 (fr) 2020-02-27 2021-02-26 Materiels et methodes de modulation d'une reponse immunitaire

Country Status (10)

Country Link
US (1) US20220306739A1 (fr)
JP (1) JP2023515199A (fr)
KR (1) KR20220147631A (fr)
CN (1) CN115484981A (fr)
AU (1) AU2021225870A1 (fr)
CA (1) CA3173268A1 (fr)
IL (1) IL295897A (fr)
MX (1) MX2022010664A (fr)
TW (1) TW202144415A (fr)
WO (1) WO2021173896A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201706128PA (en) 2015-01-27 2017-08-30 Lava Therapeutics B V Single domain antibodies targeting cd1d
BR112021005184A8 (pt) 2018-09-19 2022-08-16 Lava Therapeutics B V Imunoglobulina cd1d de dupla ação
MA55305A (fr) 2019-03-11 2022-01-19 Janssen Biotech Inc Anticorps bispécifiques anti-v béta 17/anti-cd123
KR20220017892A (ko) * 2019-05-08 2022-02-14 얀센 바이오테크 인코포레이티드 T세포 매개 면역의 조절을 위한 물질 및 방법
WO2021127185A1 (fr) 2019-12-17 2021-06-24 The Board Of Regents Of The University Of Texas System Nouveaux anticorps ddr1 et leurs utilisations
MX2023000448A (es) 2020-07-08 2023-04-20 Lava Therapeutics N V Anticuerpos que se unen a antígeno de membrana específico de la próstata (psma) y receptores de celulas t gamma-delta.
WO2022056197A1 (fr) 2020-09-11 2022-03-17 Janssen Biotech, Inc. Molécules de ciblage immunitaire et leurs utilisations
WO2022056192A1 (fr) 2020-09-11 2022-03-17 Janssen Biotech, Inc. Méthodes et compositions pour moduler l'immunité médiée par la chaîne bêta
US20220089737A1 (en) * 2020-09-11 2022-03-24 Janssen Biotech, Inc. Multi-specific immune targeting molecules and uses thereof
TW202233674A (zh) 2020-10-28 2022-09-01 美商健生生物科技公司 用於調節δγ鏈介導之免疫的組成物及方法
WO2024085182A1 (fr) 2022-10-18 2024-04-25 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Agent thérapeutique pour une tumeur à lymphocytes t
WO2024138213A2 (fr) * 2022-12-23 2024-06-27 The Wistar Institute Of Anatomy And Biology Inhibiteurs de siglec-9 et leurs méthodes d'utilisation pour améliorer l'efficacité immunothérapeutique
WO2025103451A1 (fr) * 2023-11-15 2025-05-22 上海盛迪医药有限公司 Protéines de liaison à trgv9 et leur utilisation médicale

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002351208A1 (en) * 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
EP1790664A1 (fr) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
JP2012505654A (ja) * 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
US10501540B2 (en) * 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
CN118638228A (zh) * 2016-12-26 2024-09-13 协和麒麟株式会社 与髓鞘少突胶质细胞糖蛋白结合的抗体
US10519236B2 (en) * 2018-01-23 2019-12-31 New York University Antibodies specific to delta 1 chain of T cell receptor
RS66901B1 (sr) * 2018-05-24 2025-07-31 Janssen Biotech Inc Anti-cd3 antitela i njihova upotreba
JOP20190116A1 (ar) * 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
KR20220017892A (ko) * 2019-05-08 2022-02-14 얀센 바이오테크 인코포레이티드 T세포 매개 면역의 조절을 위한 물질 및 방법
UY40280A (es) * 2020-03-13 2023-07-31 Janssen Biotech Inc Dominios de unión a antígeno que se unen a la proteina cd33 de la superficie de células mieloides

Also Published As

Publication number Publication date
JP2023515199A (ja) 2023-04-12
CN115484981A (zh) 2022-12-16
KR20220147631A (ko) 2022-11-03
TW202144415A (zh) 2021-12-01
MX2022010664A (es) 2022-11-30
IL295897A (en) 2022-10-01
WO2021173896A1 (fr) 2021-09-02
WO2021173896A8 (fr) 2022-10-06
AU2021225870A1 (en) 2022-10-20
US20220306739A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
CA3173268A1 (fr) Materiels et methodes de modulation d'une reponse immunitaire
US11466082B2 (en) Anti-CD33 antibodies, anti-CD33/anti-CD3 bispecific antibodies and uses thereof
US20210284731A1 (en) Methods and materials for modulating an immune response
JP2022101539A (ja) ヒト化またはキメラｃｄ３抗体
EP4228693A1 (fr) Immunité à médiation par des lymphocytes t biologiquement modifiés, matériaux et autres procédés pour la modulation d'un ensemble de différenciation iv &/ou viii
CA3194968A1 (fr) Methodes et compositions pour moduler l'immunite mediee par la chaine beta
US20210284730A1 (en) Materials and methods for modulating delta chain mediated immunity
JP2023537534A (ja) 多特異性抗ｔｃｒデルタ可変１抗体
WO2022093888A1 (fr) Compositions et procédés de modulation de l'immunité à médiation par la chaîne gamma delta
WO2022056197A9 (fr) Molécules de ciblage immunitaire et leurs utilisations
TW202342536A (zh) 多特異性抗ＴＣＲδ可變１抗體
JP2024509332A (ja) 多重特異性抗ＴＣＲδ可変部１抗体
EP4110390A1 (fr) Matériels et méthodes de modulation d'une réponse immunitaire
HK40085531A (en) Materials and methods for modulating an immune response
EP4524160A2 (fr) Compositions et procédés pour la modulation de l'immunité à médiation par chaîne bêta
CN116261567A (zh) 多功能性正交蛋白嵌合体

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220923

EEER Examination request

Effective date: 20220923

EEER Examination request

Effective date: 20220923

EEER Examination request

Effective date: 20220923

EEER Examination request

Effective date: 20220923